[Federal Register: November 19, 2008 (Volume 73, Number 224)]
[Notices]
[Page 69663-69664]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19no08-91]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-09-09AF]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960 or
send comments to Maryam Daneshvar PhD, CDC Reports Clearance Officer,
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information
[[Page 69664]]
technology. Written comments should be received within 60 days of this
notice.
Proposed Project
``Evaluation of Pharmacy Syringe Access Linked to HIV Testing for
Injection Drug Users in New York City (Pharm-HIV)''--New--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
HIV continues to be one of the leading causes of illness and death
in the US, especially among black and Hispanic communities. For
injection drug users (IDU), who are at high risk of acquiring HIV
infection, HIV testing may not be readily accessible. In 2001, the New
York State Legislature established an Expanded Syringe Access
Demonstration Program (ESAP) in New York City which made syringes
available through participating pharmacies for injection drug users.
ESAP thus helped to reduce the burden of HIV by increasing access to
sterile syringe sources. The ESAP allows for regular contact between
pharmacists and their injection-drug-using syringe customers, thus
paving the way for pharmacies to act as access points to health and
social services among IDU customers. The expansion of pharmacy services
to include referrals for injection-drug-using syringe customers is
based on the successes of ESAP, which provides many services beyond
syringe exchange.
This project involves two kinds of studies: testing service models
at pharmacies and, interviewing individuals regarding the availability
of syringes through pharmacies. For testing service models CDC will
collaborate with the New York Academy of Medicine (NYAM) to implement
this project for a period of three years.
The NYAM will identify 12 ESAP pharmacies in East Harlem, New York
City; ten of which will test a model that refers injection-drug-using
syringe customers for HIV testing to local HIV testing sites. Two ESAP
pharmacies will evaluate the feasibility of offering and performing HIV
counseling and testing in the pharmacy for injection-drug-using syringe
customers.
Two types of respondents will provide the individual-level data;
forty-eight adult (age >=18 yrs) pharmacy staff members will be
surveyed to learn about pharmacy staff attitudes and behaviors
regarding HIV testing and referral. The other respondent group will be
442 adult (age >=18 yrs) injection-drug-using syringe customers who
will complete a brief quantitative interview after HIV referral or HIV
testing is offered to them. HIV-seropositive injection-drug-using
syringe customers identified during HIV testing will be immediately
linked to social and medical services. There is no cost to respondents
other than their time.
Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Types of data collection respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Pharmacy telephone screening and enrollment form 24 1 10/60 4
Pharmacy staff surveys--baseline, every six 48 5 20/60 80
months x 3, and at end of study................
Pharmacy staff brief surveys--monthly except 12 19 10/60 38
when 6 monthly surveys are completed...........
Pharmacy daily syringe sales log................ 12 600 5/60 600
Injection-drug-using syringe customer surveys... 442 1 30/60 221
---------------------------------------------------------------
Total....................................... .............. .............. .............. 943
----------------------------------------------------------------------------------------------------------------
Dated: November 7, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E8-27448 Filed 11-18-08; 8:45 am]
BILLING CODE 4163-18-P